"No more than a third of patients who receive medication for depression achieve the goals of therapy -- achieving and sustaining a remission," explained researcher Roger McIntyre, MD, Assistant Professor of Psychiatry, University of Toronto, and Head, Mood Disorders Clinic, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. "That would mean the majority of patients require a further pharmacological or psychosocial intervention to enhance the overall remission rates."

In a single-blind, randomized controlled study, 33 adults under the age of 66 received either extended-release venlafaxine 75 to 375mg/day or lithium 300 to 900 mg/day, and titrated every 2 weeks until clinical response was achieved.

Researchers found statistically significant changes in the subjects' scores on the Hamilton Depression Rating Scale (HDRS), from baseline (non-response rating of 16+ or partial response rating of 8-15) to end point. There was no difference between the lithium and venlafaxine groups in terms of response.

Furthermore, the shift in Clinical Global Impression-Improvement Score was also statistically significant. The data suggest that venlafaxine added to an SSRI could increase the overall effect from what was an insufficient SSRI trial, added Dr. McIntyre.

Of the 18 male patients, 9 received venlafaxine and 9 received lithium. Of the 15 females, 7 received Venlafaxine and 8 received lithium. [PLEASE CONFIRM.]Patients recruited to the study had been on antidepressants, including citalopram, fluvoxamine, paroxetine, fluoxetine, and sertraline.

"We found that lithium and venlafaxine were very similar in their overall efficacy as an adjunct strategy to the SSRI," said Dr. McIntyre. "There were no differences between the 2 groups in terms of side effects either."

Adverse events were reported in 87.5% of patients who received venlafaxine XR and in 88% of patients who received lithium

"We need to do a randomized controlled trial where we would take patients who have failed on an SSRI, adding possible other agents to see what the effect would be," concluded Dr. McIntyre.

This study was sponsored by Wyeth Pharmaceuticals Inc.


[Presentation title: "A Single-blind, Randomized Lithium-controlled Efficacy and Safety Trial of Venlafaxine (Effexor XR) in Subjects Experiencing a Major Depressive Episode (According to DSM-IV Criteria) Who Are Partial or Non-responders to SSRI Anti-depressants." Abstract 55]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.